Better coordination in development and review of vaccines is needed.

FDA Prioritizes Process Improvements

Advances in technology are accelerating the development and manufacture of subunit vaccines.

Subunit Vaccines and the Fight Against COVID-19

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients

Topic

Articles

The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.

EMA Recommends Adapted Spikevax Vaccine

The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.

EMA Extends Use of COVID-19 Vaccines to Children

FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.

FDA Authorizes Bivalent COVID-19 Boosters for Children Ages Five and Older

Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.

Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

FDA Authorizes Bivalent COVID-19 Boosters

Novavax’s COVID-19 vaccine, Nuvaxovid, can now be given to adolescents aged 12 to 17 in the UK.

MHRA Grants Novavax COVID-19 Vaccine Expanded Conditional Marketing Authorization 

Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.

Moderna Files Suit Against Pfizer and BioNTech

Anthony Fauci announced that he plans to step down as Director of the National Institute of Allergy and Infectious Diseases in December 2022.

Anthony Fauci to Step Down in December

The United Kingdom has approved Moderna’s bivalent COVID-19 vaccine, which targets the original variant and Omicron.

UK Approves First Bivalent COVID-19 Booster Vaccine

Moderna and the European Commission have amended their agreement to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the company’s Omicron-containing bivalent vaccines for supply in 2022.

COVID-19 Update

FDA Prioritizes Process Improvements

Subunit Vaccines and the Fight Against COVID-19

Meeting the Demand for Lipid Excipients